Ann Lab Med.  2014 Mar;34(2):127-133. 10.3343/alm.2014.34.2.127.

Clinical Validation of AdvanSure GenoBlot Assay as Primary Screening and Test of Cure for Human Papillomavirus Infection

• Kahng J
• Oh EJ
• Lee HN
• Lee DW
• Kim Y

• KMID: 1791905
• DOI: http://doi.org/10.3343/alm.2014.34.2.127

Abstract

BACKGROUND
Clinical specificity and sensitivity are essential factors in the adoption of a human papillomavirus (HPV) test as a primary screening tool and test of cure after treatment of cervical cancer and precancerous lesions (High-Risk-Lesion). Using histologically-confirmed High-Risk-Lesion-patient specimens with postoperative follow-ups, we performed clinical validation of the AdvanSure GenoBlot Assay (GenoBlot; LG Life Sciences, Korea).
METHODS
The study population included 100 cases with High-Risk-Lesion, 96 with high-risk genotype positive and cervical intraepithelial neoplasia (CIN) 1 or better, and 39 with HR-negative and better than CIN 1. Forty-eight High-Risk-Lesion cases received follow-up HPV exams after surgery. For validation as a test of cure, 48 preoperative specimens (PreOP) and 78 postoperative specimens (PostOP) from 48 subjects were separately analyzed. The results of HPV DNA chip tests (HPVDNAChip; BioMedLab Co., Korea) and sequencing were cross-compared.
RESULTS
The concordance rates for each genotype between HPVDNAChip and GenoBlot were between 96.3-100%. The accuracy of HPVDNAChip and GenoBlot was 87.9% and 96.6%, respectively. Genotype-based specificity for High-Risk-Lesion detection was higher than 87% for both assays; genotype 16 showed the highest sensitivity. In the PostOP group, the positive rates for HPVDNAChip and GenoBlot were 30.8% and 47.4%, respectively.
CONCLUSIONS
GenoBlot showed a higher positive rate than HPVDNAChip for each genotype, with concordance rate and accuracy being similar to previous reports. As a test of cure, GenoBlot performed better than the HPVDNAChip.

Keyword

HPV; Genotype; Cervical cancer; Screening; Clinical validation; Test of cure

MeSH Terms

Adolescent
Adult
Aged
*Blotting, Southern
DNA, Viral/*analysis
Female
Genotype
Humans
Middle Aged
Papillomaviridae/*genetics
Papillomavirus Infections/*diagnosis/pathology/therapy
Reagent Kits, Diagnostic
*Real-Time Polymerase Chain Reaction
Sequence Analysis, DNA
Young Adult
DNA, Viral
Reagent Kits, Diagnostic

Reference

1. Arbyn M, Ronco G, Meijer CJ, Naucler P. Trails comparing cytology with human papillomavirus screening. Lancet Oncol. 2009; 10:935–936. PMID: 19796748.

2. Poljak M, Oštrbenk A. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies. Acta Dermatovenerol Alp Panonica Adriat. 2013; 22:43–47. PMID: 23836358.

3. Cuschieri K, Hardie A, Hovland S, Hoaas B, Karlsen F, Cubie H. Comparison of the sensitivities of three commercial assays for detection of the high risk HPV types 16, 18 and 45. J Virol Methods. 2013; 193:147–150. PMID: 23727117.

4. Lloveras B, Gomez S, Alameda F, Bellosillo B, Mojal S, Muset M, et al. HPV testing by cobas HPV test in a population from Catalonia. PLoS One. 2013; 8:e58153. PMID: 23483984.

5. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol. 2011; 12:880–890. PMID: 21865084.

6. Satoh T, Matsumoto K, Fujii T, Sato O, Gemma N, Onuki M, et al. Rapid genotyping of carcinogenic human papillomavirus by loop-mediated isothermal amplification using a new automated DNA test (Clinichip HPVTM). J Virol Methods. 2013; 188:83–93. PMID: 23219807.

7. Herraez-Hernandez E, Alvarez-Perez M, Navarro-Bustos G, Esquivias J, Alonso S, Aneiros-Fernandez J, et al. HPV Direct Flow CHIP: a new human papillomavirus genotyping method based on direct PCR from crude-cell extracts. J Virol Methods. 2013; 193:9–17. PMID: 23680093.

8. Tao P, Zheng W, Wang Y, Bian ML. Sensitive HPV genotyping based on the flow-through hybridization and gene chip. J Biomed Biotechnol. 2012; 2012:938780. PMID: 23193367.

9. Hwang Y, Lee M. Comparison of the AdvanSure human papillomavirus screening real-time PCR, the Abbott RealTime High Risk human papillomavirus test, and the Hybrid Capture human papillomavirus DNA test for the detection of human papillomavirus. Ann Lab Med. 2012; 32:201–205. PMID: 22563555.

10. Song HJ, Lee JW, Kim BG, Song SY, Bae DS, Kim DS. Comparison of the performance of the PANArray™ HPV test and DNA chip test for genotyping of human papillomavirus in cervical swabs. BioChip J. 2010; 4:167–172.

11. An H, Song KS, Nimse SB, Kim J, Nguyen V, Ta VT, et al. HPV 9G DNA chip: 100% clinical sensitivity and specificity. J Clin Microbiol. 2012; 50:562–568. PMID: 22170909.

12. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005; 32(Suppl 1):S16–S24. PMID: 15753008.

13. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009; 10:321–322. PMID: 19350698.

14. Arney A, Bennett KM. Molecular diagnositics of human papillomavirus. Lab Med. 2010; 41:523–530.

15. Lee GY, Kim SM, Rim SY, Choi HS, Park CS, Nam JH. Human papillomavirus (HPV) genotyping by HPV DNA chip in cervical cancer and precancerous lesions. Int J Gynecol Cancer. 2005; 15:81–87. PMID: 15670301.

16. Um TH, Lee EH, Chi HS, Kim JW, Hong YJ, Cha YJ. Comparison of HPV genotyping assays and Hybrid Capture 2 for detection of high-risk HPV in cervical specimens. Ann Clin Lab Sci. 2011; 41:48–55. PMID: 21325255.